Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

586
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
586
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

361
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
361
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

459
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
459
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

583
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
583
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

456
Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
456

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Irreversible Electroporation for the Treatment of Pediatric Adenotonsillar Hypertrophy.

Journal of clinical medicine·2026
Same author

Irreversible Electroporation for Tonsillar Ablation in Adults.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026
Same author

The Diabetic Nose: A Narrative Review of Rhinologic Involvement in Diabetes (1973-2025).

Journal of clinical medicine·2026
Same author

Using Quantitative Masticatory Dysfunction to Inform Pain Management in Trigeminal Neuralgia Through Electromyographic Monitoring.

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·2025
Same author

A Structured Narrative Review of the OSA-T2DM Axis.

Journal of clinical medicine·2025
Same author

Oxidative stress in patients with nasal respiratory impairment and OSAS.

Sleep & breathing = Schlaf & Atmung·2025

Related Experiment Video

Updated: Sep 11, 2025

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

30.9K

HMGB1 as a Key Modulator in Nasal Inflammatory Disorders: A Narrative Review.

Desiderio Passali1, Luisa Maria Bellussi1, Mariaconsiglia Santantonio2

  • 1ENT Clinic, University of Siena, 53100 Siena, SI, Italy.

Journal of Clinical Medicine
|August 14, 2025
PubMed
Summary

High Mobility Group Box 1 (HMGB1) is a key player in nasal inflammation, influencing conditions like chronic rhinosinusitis. Targeting HMGB1 offers potential for new diagnostic and therapeutic strategies in these diseases.

Keywords:
HMGB1allergic rhinitischronic rhinosinusitisglycyrrhizinrhinitis

More Related Videos

Intra-tracheal Administration of Haemophilus influenzae in Mouse Models to Study Airway Inflammation
09:56

Intra-tracheal Administration of Haemophilus influenzae in Mouse Models to Study Airway Inflammation

Published on: March 2, 2016

10.4K
Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

1.9K

Related Experiment Videos

Last Updated: Sep 11, 2025

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

30.9K
Intra-tracheal Administration of Haemophilus influenzae in Mouse Models to Study Airway Inflammation
09:56

Intra-tracheal Administration of Haemophilus influenzae in Mouse Models to Study Airway Inflammation

Published on: March 2, 2016

10.4K
Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

1.9K

Area of Science:

  • Immunology
  • Otorhinolaryngology
  • Molecular Biology

Background:

  • High Mobility Group Box 1 (HMGB1) acts as a damage-associated molecular pattern molecule, mediating inflammation in various diseases.
  • This review focuses on the critical role of HMGB1 in nasal inflammatory disorders, including chronic rhinosinusitis and allergic rhinitis.

Purpose of the Study:

  • To review the current literature on the role of HMGB1 in nasal inflammatory diseases.
  • To explore HMGB1 as a potential diagnostic biomarker and therapeutic target for these conditions.

Main Methods:

  • Comprehensive literature review using PubMed.
  • Focus on studies published from 2015 onwards.
  • Targeted search for HMGB1's role in nasal inflammatory diseases.

Main Results:

  • HMGB1 significantly amplifies and modulates inflammatory responses via multiple receptor interactions.
  • HMGB1 regulates cytokine production, epithelial-mesenchymal transition, and tissue remodeling, especially in eosinophilic chronic rhinosinusitis.
  • Therapeutic agents like glycyrrhetinic acid and PPAR-γ agonists show promise in modulating HMGB1 activity.

Conclusions:

  • HMGB1 is a promising diagnostic biomarker and therapeutic target for nasal inflammatory diseases.
  • Further translational research is needed to fully understand HMGB1's complex mechanisms and therapeutic potential.
  • HMGB1's role as an "inflammatory crossroads" highlights the need for targeted investigations.